Health Protection Surveillance Centre, Health Service Executive, Dublin, Ireland.
National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2001741.
BackgroundRobust data on SARS-CoV-2 population seroprevalence supplement surveillance data in providing evidence for public health action.AimTo conduct a SARS-CoV-2 population-based seroprevalence survey in Ireland.MethodsUsing a cross-sectional study design, we selected population samples from individuals aged 12-69 years in counties Dublin and Sligo using the Health Service Executive Primary Care Reimbursement Service database as a sampling frame. Samples were selected with probability proportional to the general population age-sex distribution, and by simple random sampling within age-sex strata. Antibodies to SARS-CoV-2 were detected using the Abbott Architect SARS-CoV-2 IgG Assay and confirmed using the Wantai Assay. We estimated the population SARS-CoV-2 seroprevalence weighted for age, sex and geographic area.ResultsParticipation rates were 30% (913/3,043) and 44% (820/1,863) in Dublin and Sligo. Thirty-three specimens had detectable SARS-CoV-2 antibodies (1.9%). We estimated weighted seroprevalences of 3.12% (95% confidence interval (CI): 2.05-4.53) and 0.58% (95% CI: 0.18-1.38) for Dublin and Sligo, and 1.69% (95% CI: 1.13-2.41) nationally. This equates to an estimated 59,482 (95% CI: 39,772-85,176) people aged 12-69 years nationally having had infection with SARS-CoV-2, 3.0 (95% CI: 2.0-4.3) times higher than confirmed notifications. Ten participants reported a previous laboratory-confirmed SARS-CoV-2 -infection; eight of these were antibody-positive. Twenty-five antibody-positive participants had not reported previous laboratory-confirmed infection.ConclusionThe majority of people in Ireland are unlikely to have been infected with SARS-CoV-2 by June-July 2020. Non-pharmaceutical public health measures remained key pending widespread availability of vaccination, and effective treatments.
背景
关于 SARS-CoV-2 人群血清流行率的可靠数据为公共卫生措施提供了证据。
目的
在爱尔兰进行基于人群的 SARS-CoV-2 血清流行率调查。
方法
我们使用横断面研究设计，从都柏林和斯莱戈县年龄在 12-69 岁的个体中使用卫生服务执行初级保健报销服务数据库作为抽样框架选择人群样本。使用与一般人群年龄性别分布成正比的概率和年龄性别层内的简单随机抽样选择样本。使用 Abbott Architect SARS-CoV-2 IgG 测定法检测 SARS-CoV-2 抗体，并使用万泰测定法确认。我们根据年龄、性别和地理区域对人群 SARS-CoV-2 血清流行率进行了加权估计。
结果
都柏林和斯莱戈的参与率分别为 30%（913/3043）和 44%（820/1863）。33 个标本检测到 SARS-CoV-2 抗体（1.9%）。我们估计都柏林和斯莱戈的加权血清流行率分别为 3.12%（95%置信区间[CI]：2.05-4.53）和 0.58%（95%CI：0.18-1.38），全国为 1.69%（95%CI：1.13-2.41）。这相当于全国 12-69 岁人群中估计有 59482 人（95%CI：39772-85176）感染了 SARS-CoV-2，是确诊病例的 3.0 倍（95%CI：2.0-4.3）。有 10 名参与者报告了以前实验室确诊的 SARS-CoV-2 感染；其中 8 人抗体阳性。25 名抗体阳性的参与者未报告以前实验室确诊的感染。
结论
截至 2020 年 6-7 月，爱尔兰大多数人不太可能感染 SARS-CoV-2。在广泛提供疫苗接种和有效治疗之前，非药物公共卫生措施仍然是关键。
